Aminoglycoside substrate profile analysis of clinical isolates as well as of laboratory-derived cured strains and transconjugants revealed 2"-aminoglycoside phosphotransferase and 3'-aminoglycoside phosphotransferase (III) phosphorylating enzymes, AAC-6' acetylating activity above that attributable to the intrinsic activity characteristic of S. faecium, and a streptomycin adenylylating enzyme. All three isolates carried a 51-megadalton plasmid. Curing of this plasmid or conjugative transfer into susceptible recipients was associated with the loss or acquisition of high-level gentamicin resistance, respectively. Loss of high-level gentamicin resistance was also observed when curing techniques resulted in a decrease in the size of this plasmid equivalent to a 10-megadalton deletion. Transferable, high-level resistance to gentamicin and other aminoglycosides, which was previously recognized in S. faecalis, has now emerged in clinical isolates of S. faecium, with the attendant concerns for possible spread.
High-level resistance to gentamicin among clinical isolates of Streptococcus (Enterococcus) faecalis was first reported in 1979 (8) . The genetic determinants encoding the aminoglycoside-modifying enzymes responsible for high-level gentamicin resistance (MIC, >2,000 ,ug/ml) were found to be plasmid-mediated and transmissible in vitro into suitable recipient strains (3, 15) . Since that time, isolates of S. faecalis with high-level resistance to gentamicin as well as to other clinically available aminoglycosides have been reported worldwide (2, 22) and currently make up a significant proportion of clinical enterococcal isolates at some centers (28) . The importance of these observations rests in the fact that high-level aminoglycoside resistance confers resistance to bactericidal synergism between that aminoglycoside and cell wall-active antibiotics (3, 15 (18) . Synergism was defined as a 2'100-fold killing by the aminoglycoside-penicillin combination at 24 h of incubation compared with the bactericidal effect of the penicillin alone.
Curing of resistance determinants. Initial attempts to cure strains of high-level (>2,000 ,ug/ml) resistance to gentamicin with novobiocin (14) were unsuccessful. Therefore, a method with ciprofloxacin was used (16 isolated, reidentified, and subjected to formal susceptibility testing. Conjugation experiments. Transfer of high-level gentamicin resistance determinants into recipient strains of S. faecalis JH2-7 and S. faecium GE-1 was undertaken by two mating techniques. Cross-streak agar plate mating (7) was used to maximize detection of low-frequency events. To quantitate transfer frequencies, a filter-mating procedure was used (21) . Donors and recipients were applied in ratios of 10:1, 1:1, and 1:10. Selective plates contained gentamicin (250 pLg/ml), rifampin (100 ,ug/ml), and fusidic acid (25 ,ug/ ml).
Plasmid detection. Plasmid DNA was prepared by the method of Birnboim and Doly (1) with the following modifications. Cells were grown at 35°C in dextrose phosphate broth (12 ml) to the mid-log phase, at which time glycine was added to a final concentration of 5% and incubation was continued for 1 h (23); lysozyme (5 mg/ml), sodium hydroxide (0.3 M), and sodium dodecyl sulfate (3%) were used for alkali lysis. Separation of plasmid bands was accomplished by horizontal agarose (0.7%) gel electrophoresis in 0.089 M Tris borate buffer (13) . Digestion of plasmid DNA with restriction endonucleases EcoRI and HindIII was performed under the conditions recommended by the manufacturer (Boehringer Mannheim Biochemicals, Indianapolis, Ind.).
Aminoglycoside-modifying enzymes. Aminoglycoside-modifying enzyme activity in sonic extracts of bacterial cells was determined by previously described methods (4, 11, 20) . Among the aminoglycoside analogs used were netilmicin, 6'-ethylnetilmicin, gentamicin C1 and Cla, sisomicin, and 2"-deoxysisomicin, which were generously provided by George Miller, Schering Corp., Bloomfield, N.J.
RESULTS
Strain characteristics and antimicrobial agent susceptibilities. The three high-level gentamicin-resistant clinical isolates resembled typical S. faecium strains in colony size and morphology and had strong alpha-hemolysis on horse blood agar. Sources of isolation and aminoglycoside susceptibilities are given in Table 1 . MICs of ampicillin against strains 87-Pi, 87-P2, and 87-P4 were 32, 32, and 128 ,ug/ml, respectively. All strains were resistant to erythromycin (MIC, >256 ,uglml), clindamycin (MIC, >256 ,ug/ml), and tetracycline (MIC, .16 pug/ml).
Curing experiments. Determinants of high-level resistance to gentamicin were cured after treatment with ciprofloxacin at rates of ca. 1% (1 of 103 colonies derived from strain 87-Pl; 2 of 256 colonies derived from strain 87-P2). Two of the resulting strains (87-Cl and 87-C2) were inhibited by gentamicin at 32 ,ug/ml and also lost high-level tobramycin resistance, while a third strain (87-C3) demonstrated an intermediate level of resistance to gentamicin (MIC, 500 ,ug/ ml) and retained high-level resistance to tobramycin ( Table  1) . None of the three strains was cured of high-level resistance to streptomycin or kanamycin or of resistance to macrolide antibiotics or tetracycline.
Mating experiments. Transfer of high-level gentamicin resistance to S.faecalis JH2-7 occurred at low frequencies (<2 X 10-7 per recipient) but was detected by the cross-streak mating technique. Resistance was transferred to the S. faecium recipient at frequencies of 6 x 10-6 to 1 x 10-4 per recipient, depending on the ratio of donors to recipients applied in the mating mixture. Properties of the resulting transconjugants are given in Table 1 .
Synergism studies. When ampicillin was combined with any one of several aminoglycosides, no bactericidal synergism was seen against any of the clinical isolates. Curing of high-level resistance to gentamicin restored synergism between ampicillin and gentamicin, but not kanamycin, tobramycin, or amikacin. Transfer of high-level aminoglycoside resistance into S. faecalis J142-7 or S. faecium GE-1 was accompanied by a loss of synergism between that aminoglycoside and penicillin or ampicillin.
Aminoglycoside-modifying enzymes. Aminoglycoside-modifying enzyme activities were studied in the first two clinical isolates and in their laboratory-derived strains (Table 2 ). In both clinical strains, 2"-aminoglycoside phosphotransferase (APH-2"), 3'-aminoglycoside phosphotransferase (APH-3'), and AAC-6' activities were detected, as were streptomycinadenylylating enzymes. 6'-Acetylating activity was recorded as positive only when it was greatly in excess of the low-level, chromosomally mediated enzyme activity characteristic of S. faecium (25) ( Table 2 ). Substrate profiles of the phosphorylating and acetylating enzymes of representative strains are given in Table 3 . The fact that netilmicin is a relatively poor substrate for the AAC-6' enzyme, when compared with kanamycin (15), partially obscures the fact that acetylating activities of strains 87-Pi and 87-C3 against netilmicin were approximately 200 and 25 times, respectively, those against 6'-ethylnetilmicin, indicating that 6'-acetylating activity existed in both strains. These enzymes were also found in strain 87-P4. Plasmid analysis. Clinical isolates 87-Pl and 87-P2, which were isolated 7 months'apart, demonstrated identical plasmid patterns consisting of a high-molecular-mass band of approximately 51 megadaltons (MDa) and two lower-molecular-mass bands of 10 and 6 MDa. Isolate 87-P4 also carried a 51-MDa plasmid but demonstrated a si'ngle 8-MDa lowmolecular-mass band.' Comparison of restriction fragments from plasmid DNA of the three clinical isolates sugges'ted a high degree of genetic relatedness among the high-molecular-mass plasmids of these isolates. Curing of high-level gentamicin resistance from 87-P-2 to yield 87-Cl was associated with a decreas'e in size of the high-molecular-mass plasmid to 41 MDa, which was consistent with a deletion of 10 MDa (Fig. 1) . In cured strains 87-C2 and 87-C3, the high-molecular-mass plasmid seen in the parent strain was no longer evident. The smaller plasmid bands remained unchanged in each of the cured strains. Transfer of highlevel gentamicin resistance by conjugation was associated with the acquisition of high-molecular-mass bands in strains 87-T1l and 87-T24. In strain 87-T24, the 51-MDa plasmid was transferred unchanged, while in strain 87-T1l, the apparent molecular mass of the acquired plasmid was measured at approximately 58 MDa. Despite multiple attempts, plasmid DNA could not be demonstrated in strain 87-T3. a Activity relative to kanamycin, which was equal to 100%.
b Kanamycin A, 96 to 99% (4) . DISCUSSION At a time when the increasing prevalence of highly gentamicin-resistant S. faecalis isolates has become widely appreciated (15, 28), we have documented here the emergence of high-level gentamicin resistance among clinical isolates of S. faecium as well. High-level resistance to aminoglycosides in these S. faecium strains could be attributed to the presence of aminoglycoside-modifying enzymes comparable to those seen in highly resistant S. faecalis strains (15) . The presence of APH-3' (III) in cured derivatives was deduced from differences in phosphorylation of kanamycin and tobramycin (3, 24) . Phosphorylation of sisomicin but not 2"-deoxysisomycin pointed to the presence of an APH-2" enzyme in parent strains. In two of three cured derivatives and in all three transconjugants, the presence or absence of APH-2" activity predicted coexisting AAC-6'. This observation is consistent with the recent characterization that APH-2"-AAC-6' activities of S. faecalis arise from a single bifunctional enzyme (6) . Interestingly, strain 87-C3 demonstrated considerable acetylating activity in the absence of notable APH-2" phosphorylation. It is not known whether this situation was the result of an event leading to hyperproduction of the intrinsic acetylating enzyme associated with curing of the bifunctional enzyme or to the dissociation of acquired AAC-6' and APH-2" activities, which are presumably fused under normal circumstances (6) . As has been the case with highly gentamicin-resistant S. faecalis, there was no evidence of aminoglycoside adenylyltransferase-2" (ANT-2") activity in these strains of S. faecium (3, 15) . Adenylylating activity against streptomycin was found in clinical isolates. Characterization of this activity as ANT-6 was inferred by the lack of effective adenylylation of spectinomycin (data not shown) (3, 15 ).
Loss of high-level resistance to gentamicin was associated with curing of a high-molecular-mass plasmid without a change in the content of smaller plasmid bands. In previous studies in S. faecalis, determinants for high-level gentamicin resistance have been localized to plasmids of approximately 45 to 60 MDa (8, 19, 27) , which is comparable in size to the high-molecular-mass plasmids in our strains. That genetic determinants mediating production of APH-3' and ANT-6 enzymes were not located on the high-molecular-mass plasmid was supported by experiments which demonstrated curing of the 51-MDa plasmid without loss of APH-3' and ANT-6 activities (strain 87-C2) and conjugative acquisition of the 58-MDa plasmid without acquisition of these enzymes (strain 87-Til). Previous investigations of transferable resistance markers in S. faecium have associated conjugative transfer of high-level resistance to streptomycin and kanamycin with plasmids of various sizes, but such transfer has also occurred in the absence of detectable extrachromosomal DNA in either donor or recipient strains (12) .
Because of the species-specific resistance of S. faecium to synergistic killing by combinations of penicillins with aminoglycosides that are susceptible to acetylation at the 6' position (17) and the frequent occurrence of APH-3' (III) in these isolates, gentamicin is often the only clinically available aminoglycoside that is capable of synergistically killing these bacteria when combined with a cell wall-active antibiotic. The clinical significance of high-level resistance to gentamicin is, therefore, that synergism between gentamicin and cell wall-active antimicrobial agents against such strains of S. faecium is precluded. Although strains of S. faecium possessing high-level resistance to gentamicin appear to be extremely uncommon, at least one clinical isolate, in addition to those described here, has been referred to the Centers for Disease Control (B. Metchock, R. Cooksey, B. Hill, and C. Thornsberry, 27th ICAAC, abstr. no. 1321, 1987). In assessing the potential importance of these observations, one can note that frequencies of conjugative transfer of high-level gentamicin resistance from the strains studied here (i.e., as high as 10-') are comparable to those described previously for S. faecalis strains (15) . Less than 10 years after the isolation of the first highly gentamicin-resistant strains of S. faecalis, such organisms now account for more than 50% of clinical enterococcal isolates at one institution (28) . In light of these facts, microbiologists and clinicians should remain alert to the worrisome possibility that highly gentamicin-resistant strains of S. faecium may emerge as an increasing clinical problem.
